Citations

Clear

229 citation(s) found for "Chow, W".

Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study
Gupta, Pankaj , Gupta, Kalpna , Dockter, Travis , Harlos, Elizabeth, Chow, Selina , Subbiah, Niveditha , Ruddy, Kathryn, Bazhenova, Lyudmila , Terstriep, Shelby A., Huang, Chao, Kratzke, Robert, Vokes, Everett E., Loprinzi, Charles L. , Kratzke, Robert A. , Ruddy, Kathryn J. , Bazhenova, Lyudmila , Ruddy, Kathryn J , Kratzke, Robert A , Loprinzi, Charles , Harlos, Elizabeth, Huang, Chao

Mayo Clinic

Cancers | January 26, 2026 | Volume: 18 | Issue: 3 | Pages: 373

10.3390/cancers18030373 | PMID 41681846 Get It

Background: Mu opioid receptors (MORs) in peripheral tissues mediate adverse effects of opioids that impair health-related quality of life (HRQoL) and may stimulate cancer progression via mitogenic signaling. Naloxegol, a peripherally acting MOR antagonist (PAMORA), is approved for opioid-induced constipation. Safety and efficacy of naloxegol have not been evaluated concurrently with systemic cancer therapy. Methods: We conducted a randomized, double-blind, placebo-controlled trial of naloxegol in patients with advanced lung adenocarcinoma starting first-line systemic therapy. Results: Only 50 patients were enrolled; the trial was terminated early due to slow accrual. Two of the three components of the feasibility primary endpoint were not met (accrual and PRO completion). At 6 months, FACT-L emotional well-being was better with naloxegol (p = 0.0113). There were trends towards better Trial Outcome Index (p = 0.0505) and physical well-being (p = 0.0628) with naloxegol. Bowel function favored naloxegol for constipation (p = 0.0223), rectal pain during defecation (p = 0.0075), and abdominal pain from constipation (p = 0.0113). Adverse event frequency and severity, PRO-CTCAE, urinary hesitancy, pain scores, and progression-free and overall survival were comparable between naloxegol and placebo. Conclusions: Naloxegol appears to be safe and tolerable, with a signal of improved HRQoL and previously unappreciated benefit for emotional well-being, without adverse clinical outcomes. Our findings should be confirmed in larger studies. ClinicalTrials.gov ID: NCT03087708.
Prognostic factors for 90-day survival after stereotactic radiosurgery for brain metastasis patients
Loron, Ali Gharibi , Chow, William, Pumford, Andrew D., Zhao, Conan , Keough, Michael B. , You, Hyo Bin , Do, Bobby, Schwartz, Jenna , Foote, Robert L., Mahajan, Anita , Stien, Kathy J., Link, Michael J., Yan, Elizabeth Mary, Brown, Paul D., Pollock, Bruce E., Parney, I., Chow, William D, Zhao, Conan Y, Pumford, Andrew D. , Foote, Robert L. , Routman, David M. , Link, Michael J. , Burns, Terry C. , Yan, Elizabeth, Pollock, Bruce E.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 979-987

10.3171/2025.8.jns25859 | PMID 41569738 Get It

OBJECTIVE Brain metastases significantly impact neurocognitive function and overall survival. Stereotactic radiosurgery (SRS) is a cornerstone of treatment for patients with limited metastases and expected survival beyond 3 months. Despite current guidelines, up to 20% of patients with brain metastases undergoing SRS have been reported to die within 90 days. This study retrospectively evaluated prognostic factors associated with 90-day survival after SRS, aiming to improve patient selection. METHODS The authors retrospectively analyzed a cohort of 1546 patients who underwent Gamma Knife SRS for brain metastases at their institution between 2015 and 2023. One hundred seventy patients who survived less than 90 days after SRS were identified and case matched to 170 patients who survived over 90 days. Measured variables included patient demographic characteristics, tumor characteristics, treatment history, functional status, and control of the primary cancer. The authors modeled post-SRS 90-day survival using binomial and multivariate logistic regression. RESULTS Multivariate analysis highlighted Karnofsky Performance Score (KPS) < 70 (OR 17.4, p < 0.001), prior whole-brain radiation (OR 6, p = 0.004), and focal neurological deficits (OR 3.02, p = 0.003) as significant predictors of poor survival, whereas CNS progression before SRS (OR 0.22, p < 0.001) and control of systemic cancer (OR 0.556, p = 0.002) were associated with survival < 90 days. The predictive model demonstrated acceptable performance with an area under the curve (AUC) of 0.85, accuracy of 80%, sensitivity of 87%, and specificity of 71%. CONCLUSIONS Key predictors of 90-day survival after SRS for brain metastases include functional status (KPS), control of systemic cancer, CNS progression status, and focal neurological deficits. These findings are complementary factors that can assist in making decisions and SRS patient selection.
Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102)
Wood, Marie , Pinsky, Paul F. , Novotny, Paul J. , Leevan, Elyse , Weiss, Matthias , Edelman, Dan, Watson, Mark A. , Patriotis, Christos , Merker, Jason D. , Prorok, Philip C. , Wen, Yujia , Rubinstein, Wendy S. , Dragnev, Konstantin H. , Katki, Hormuzd A. , Chow, Selina , Kemeny, Margaret, Gautam, Umang, Reddy, Aswanth , Burak, William E. , Piantadosi, Steven , Minasian, Lori M. , Wood, Marie E , Edelman, Dan C , Watson, Mark , Dragnev, Konstantin , Skarlupka, Amanda L , Katki, Hormuzd A , Chow, Selina , Kemeny, Margaret , Piantadosi, Steven , Weiss, Matthias

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 5, 2026 | Volume: 118 | Issue: 4 | Pages: 730-736

10.1093/jnci/djag001 | PMID 41499420 Get It

Abstract Background Reference sets are needed to evaluate performance of multi-cancer detection (MCD) assays. The National Cancer Institute funded the Alliance reference set study to assess MCDs for use in future trials. Methods Individuals with cancer and controls were recruited; blood specimens were collected prior to cancer treatment. A performance evaluation study was designed utilizing reference set samples. Companies (n = 6) were selected to participate based on review of performance data and ability to utilize the blood collection tube. Companies received samples from cancer types their assay was designed to detect (“targeted”), plus additional “non-targeted” and control samples. Companies reported positive/negative calls, risk scores, and tissue-of-origin (TOO) predictions. Sensitivity was computed for early (I-II) and late (III-IV) stage cases, based on positive/negative calls (SEPN) and at fixed 98% specificity (SE98). Specificity and TOO accuracy were computed. Results Five hundred and forty nine cases (encompassing 13 cancer types) and 413 controls from the reference set were included in the study. Companies assessed samples from median 6 (range 5-9) targeted cancer types and median 8 (range: 7-11) overall cancer types. Median (range) specificity was 92.3% (76.5%-98.5%). Median (range) SEPN was 32% (25%-42%) for early stage and 73% (48%-89%) for late stage; while median (range) SE98 was 19% (8%-35%) for early stage and 66% (13%-79%) for late stage. Median sensitivity for non-targeted types was 40% (early stage) and 52% (late stage). Median (range) TOO accuracy (primary predicted site) was 75% (64%-78%). Conclusions Sensitivity and specificity varied widely across assays with early-stage sensitivity substantially lower than late-stage sensitivity. Clinical Trial Registration Number ClinicalTrials.gov identifier NCT05334069.
Epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Hawaii
Takaoka, Kensuke , Tanariyakul, Manasawee , Miyashita, Akihiro , Sumida, Kenneth, Nishimura, Yoshito , Chow, Dominic C.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7396-7396

10.1182/blood-2025-7396 Get It

Abstract Introduction: The epidemiology and clinical characteristics of familial myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) remain poorly understood, particularly among Native Hawaiians and Other Pacific Islanders (NHOPI). Methods: To investigate the real-world evidence in this area, we conducted a retrospective study at the Queen's Medical Center (QMC), Hawaii's largest tertiary referral hospital. The data was gathered from QMC's electronic medical record. Familial MDS or familial AML patients in this study were defined as MDS or AML occurring in a patient with a family history of MDS and/or AML. Patients with acute promyelocytic leukemia (APL), as well as those with a family history of APL, were excluded given the differences in disease characteristics and its genetic phenotype from other AML subtypes. Unspecified leukemia was defined when a patient had a family history of leukemia but the specific subtype was unavailable. Some patients underwent comprehensive panel testing, while others had targeted next-generation sequencing (NGS) assays ordered at the discretion of their treating physicians. NGS was performed at Clinical Laboratory Improvement Amendments (CLIA)-certified commercial laboratories. NGS panels typically included the following genes: ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53, and WT1. Results: Among 1,686 MDS/AML patients presented between January 2012 and July 2023, 12 (0.71 %) had familial MDS/AML and 25 (1.48%) had a family history of unspecified leukemia. While no NHOPI were identified among familial MDS/AML cases, 20% of patients with a family history of unspecified leukemia were NHOPI. The median age at diagnosis of familial MDS/AML was 70 years, and 50% of familial MDS patients had MDS with low blasts based on the World Health Organization 2022 classification. Based on International Consensus Classification 2022 criteria, 25% had MDS, not otherwise specified (NOS) with multilineage dysplasia, and 25% had MDS, NOS with single lineage dysplasia. Among the eight patients with familial MDS, the median overall survival (OS) was 12.7 years, with an estimated 5-year OS rate of 75.0% (95% CI: 12.8–96.1), based on Kaplan–Meier analysis. In contrast, the three patients with familial AML had a median survival of 10.2 months and a 3-year OS estimate of 33.3% (95% CI: 0.90–77.4). For patients with a family history of unspecified leukemia, the median survival was not reached during the follow-up period. The estimated 5-year OS rate was 53.3% (95% CI: 12.5–82.7) for the 10 familial MDS cases and 53.3% (95% CI: 20.9–77.3) for the 13 familial AML cases. When combining all familial cases, the median OS for familial MDS (n = 18) was 12.7 years with a 5-year OS rate of 61.9% (95% CI: 26.8–84.0). The median OS for familial AML (n = 16) was 0.90 years, and the estimated 5-year OS rate was 48.2% (95% CI: 20.8–71.3). When all cases were combined, there was no statistically significant difference in overall survival between patients with familial AML (n = 16) and those with familial MDS (n = 18), based on the log-rank test (p = 0.22). Regarding NGS, ASXL1 mutations were the most frequent in the cohort, detected in six of the 32 NGS tests performed (18.8%). Among patients with familial MDS, recurrent somatic mutations were observed in several genes. ASXL1 mutations were identified in two patients; one had a brother with MDS, and the other had a maternal uncle with unspecified leukemia. DNMT3A mutations were also found in two patients with familial MDS; one had a brother with MDS, and the other had a paternal uncle with MDS. SRSF2 mutations were detected in two patients; one had a brother with MDS, and the other had a granddaughter with leukemia. Additionally, SF3B1 mutations were found in two patients; one had a mother with MDS, and the other had a paternal uncle with MDS. Two patients with familial AML were found to have ASXL1 mutation, both with fathers who had unspecified leukemia. Otherwise, no other repeated mutations were found. None of the cases involved NHOPI patients. Conclusion: Our study offers new insights into familial MDS/AML within Hawaii's multiethnic population. Although no NHOPI patients were identified among the familial cases, our findings underscore the genetic heterogeneity and clinical variability of these disorders.
SURG-22. Awake speech mapping coupled with intraoperative MRI is associated with greater extent of resection in language eloquent diffuse glioma surgery
Keough, Michael B. , Chow, William, Reilly, Charles S., Loron, Ali Gharibi , Parney, Ian, Reilly, Charles

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v399-v399

10.1093/neuonc/noaf201.1579 Get It

Abstract BACKGROUND Awake craniotomy with speech mapping remains a gold standard for achieving maximal safe resection of diffuse gliomas located in eloquent cortex. Significant practice variability exists with regards to patient selection, speech mapping paradigms, aggressiveness of resection, and use of other adjuncts. We report our experience with speech mapping procedures for patients with diffuse gliomas, comparing cases performed with and without intraoperative MRI. METHODS A single-surgeon retrospective review of 148 consecutive awake craniotomy procedures, from 2008-2024, was performed. We recorded baseline patient characteristics, speech mapping findings, post-operative course, and volumetric extents of resection. Multivariate regression analyses were performed for factors predictive of permanent aphasia and residual tumor volume. RESULTS Speech mapping was performed in 95% of cases, with positive speech areas found in 49% of cases. Intraoperative MRI cases (75% of total) had significantly greater extent of resection (87.4% vs. 78.6%, p=0.03) despite equivalent pre-operative volumes. Post-operative new/worsened aphasia was 15% for mild and 5% for moderate symptoms, and this was associated with reduced rates of return to work (54% vs 78%, p=0.04). Predictors of recovery from aphasia were extent of resection (OR 1.1, p=0.006) and 90-day disease progression (OR 0.06, p=0.04). Predictors of residual tumor volume were pre-operative tumor volume (β 0.3, p&lt;0.001), identification of after-discharge potentials during speech mapping (β -9.7, p&lt;0.001), and pre-operative functional status (β -0.3, p=0.02). Overall survival was impacted by presence of contrast enhancement (p=0.0002), tissue diagnosis (p&lt;0.0001), and WHO grade (p&lt;0.0001). CONCLUSIONS Awake craniotomy with speech mapping remains a valuable strategy for achieving maximal safe resection of diffuse gliomas, with the majority of patients returning to baseline level of functioning. New/worsened aphasia is the biggest risk of surgery, which significantly impacts patient quality of life. Intraoperative MRI can be considered as an adjunctive tool for awake speech mapping during glioma surgery.
INNV-12. Clinical utility of repeat brain biopsy in recurrent or refractory primary CNS lymphoma – a diagnostic dilemma
Malik, Noor , Chow, William, Loron, Ali Gharibi , You, Hyo Bin , Kendall, Nicholas , Keough, Michael B. , Parney, Ian, Malik, Noor , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v227-v227

10.1093/neuonc/noaf201.0901 Get It

Abstract OBJECTIVE Despite advancements in therapy and improved survival rates for patients with primary central nervous system lymphoma (PCNSL), the optimal management strategy for recurrent or refractory PCNSL (r/r PCNSL) remains undefined. In such cases, repeat brain biopsy is often performed to confirm disease recurrence, though its diagnostic and therapeutic value is uncertain. This study evaluates whether repeat brain biopsy provides new, actionable diagnostic insights that influence treatment decisions. METHODS A retrospective analysis was conducted on patients with a confirmed diagnosis of PCNSL who underwent repeat brain biopsy for suspected recurrent or refractory disease between 2005 and 2023. Patients with a history of other CNS neoplasms, demyelinating disorders, or active systemic disease were excluded. RESULTS Twenty patients met inclusion criteria (55% female), with a mean age at biopsy of 56 years in the PCNSL group and 61 years in the r/r PCNSL group. While the overall distribution of presenting symptoms did not significantly differ (p = 0.2), gait instability, weakness, and cognitive decline were more common in r/r PCNSL. PCNSL more often presented with single lesions, while r/r PCNSL had predominantly multiple lesions (p &lt; 0.05). Periventricular enhancement was significantly more frequent in r/r PCNSL (p &lt; 0.05), though other radiologic features were comparable. Repeat biopsy confirmed DLBCL in 90% of cases; no infections or alternate malignancies were identified. Diagnostic clarification was the primary indication for repeat biopsy. Chemotherapy regimens were altered in 50% of post-biopsy cases, without a corresponding difference in overall survival (p = 0.79). Procedure-related morbidity was observed in three patients (15%). CONCLUSIONS The second biopsy in most cases reaffirmed the original diagnosis of diffuse large B cell lymphoma. Although biopsy results led to treatment adjustments; these changes did not affect overall survival.
RADT-01. PROGNOSTIC FACTORS FOR 90-DAY SURVIVAL AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASIS PATIENTS
Loron, Ali Gharibi , Chow, William, Pumford, Andrew D. , Zhao, Conan , Keough, Michael B. , You, Hyo Bin , Do, B., Schwartz, Jenna R, Foote, Robert L. , Mahajan, Anita , Steinman, Kevin J, Link, Michael J., Yan, Elizabeth , Brown, Paul D. , Pollock, Bruce E. , Schwartz, Jenna R, Routman, David M. , Steinman, Kevin J, Link, Michael J. , Burns, Terry C. , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v92-v92

10.1093/neuonc/noaf201.0372 Get It

Abstract Brain metastases significantly impact neurocognitive function and overall survival. Stereotactic radiosurgery (SRS) is a cornerstone of treatment for patients with limited metastases and expected survival beyond three months. Despite current guidelines, up to 20% of patients with brain metastases undergoing SRS have been reported to die within 90 days. This study retrospectively evaluates prognostic factors associated with 90-day survival after SRS, aiming to improve patient selection. We retrospectively analyzed a cohort of 1,546 patients who underwent Gamma Knife SRS for brain metastases at our institution between 2015 and 2023. One hundred seventy patients who survived fewer than 90 days post-SRS were identified and case-matched to 170 patients who survived over 90 days. Measured variables included patient demographics, tumor characteristics, treatment history, functional status, and control of the primary cancer. We modeled post-SRS 90-day survival using binomial and multivariate logistic regression. Multivariate analysis highlighted Karnofsky Performance Status (KPS) &lt; 70 (OR: 17.4, p &lt; 0.001), prior whole brain radiation (OR: 6, p = 0.004), and focal neurological deficits (OR: 3.02, p = 0.003) as significant predictors of early deaths, while CNS progression before SRS (OR: 0.22, p &lt; 0.001) and control of systemic cancer (OR: 0.556, p = 0.002) were associated with a less than 90-day survival. The predictive model demonstrated acceptable performance with an area under the curve (AUC) of 0.85, accuracy of 80%, sensitivity of 87%, and specificity of 71%. Key predictors of 90-day survival following SRS for brain metastases include functional status (KPS), control of systemic cancer, CNS progression status, and focal neurologic deficits. These findings are complementary factors that can assist in making decisions and SRS patient selection.
Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship
Paras, Molly L , Stead, Wendy , Bisono, Bismarck , Pottinger, Paul S. , Aziz, Rania S Abdel, Aziz, Mariam, Balba, Gayle , Blackburn, Brian G. , Butt, Saira , Chow, Brian , Graber, Christopher J. , Muñoz-Gómez, Sigridh , Pellegrino, Rachael , Schultz, Sara , Shnekendorf, Rachel, Jezek, Amanda, Martin, Allan , Group, For the Infectious Diseases Society of America Training Program Directors Community of Practice and Working, Angarone, Michael , Arnold, Forest, Bartash, Rachel , Bhanot, Nitin , Bhatt, Pinki J. , Bittner, Marvin J. , Blyth, Dana M , Carey, A., Cerne, Carlie, Donaghy, Henry, Echevarria, Leonor, Jose, Jo-Ann, Kodiyanplakkal, Rosy Priya , Román, F, Garcia, Luis Medina, Lora, Alfredo J Mena , Miko, Benjamin A. , Mitra, Subhashis , Osorio, Georgina, Patel, Mukesh, Pinargote, Paulette, Salas, Natalie Mariam , Sellers, Christopher J., Tang, Michael , Tischendorf, Jessica S , Trinh, Sonya, Viehman, J Alex, Vielemeyer, Ole, Wooten, Darcy , Bisono Garcia, Bismarck , Martin, Arlene , Luther, Vera P , Pottinger, Paul , Aziz, Rabita, Luther, Vera , Group, For the Infectious Diseases Society of America Training Program Directors Community of Practice and Working, Arnold, Forest, Bhowmick, Tanaya , Carey, Adrienne L, Dare, Ryan K , Jose, Jo-Ann, Gil, Raul Macias , Roman, Francisco Machiavello, Garcia, Luis Medina, Razonable, Raymund R. , Trinh, Sonya, Viehman, J Alex

Mayo Clinic

Open Forum Infectious Diseases | November 9, 2025 | Volume: 12 | Issue: 12 | Pages: No page available

10.1093/ofid/ofaf677 | PMID 41322240 Get It

Abstract Advocacy has long been at the core of the infectious diseases (ID) field, with clinicians and researchers advocating to ensure patients can access the care they need on an individual and global scale. The Infectious Diseases Society of America Training Program Directors’ (PD) Committee met in 2024 and discussed ways that advocacy is and should be incorporated into fellowship training, as well as highlighted the role PDs play in advocating for their trainees. Policies with a negative impact on ID clinical care, public health, and research underscore the importance of mobilizing the field of ID to advocate for the patients and communities we serve, as well as for ourselves. This paper presents ideas generated at this meeting and is meant to serve as a reference for ID PDs, as well as the wider ID community, as a call to action for teaching and participating in advocacy work.
Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial
Ivory, Joannie M. , Wheeler, Stephanie B. , Drier, Sarah , Paskett, Electra D. , Naughton, Michelle J. , McCue, Shaylene , Wills, Rachel, Williams, Kayla , Chow, Selina , Reeder‐Hayes, Katherine E. , Gunn, Heather J., Paskett, Electra D , Wheeler, Stephanie B , Gunn, Heather , Williams, Kayla, Charlot, Marjory

Mayo Clinic

JCO Oncology Advances | October 27, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00029 | PMID 41585327 Get It

PURPOSE Lack of race- and age-diversity in clinical trials adversely affects generalizability of trial results and equity of trial access. Research on barriers to representative accrual has focused on patient-level factors. We aimed to define site-level factors affecting the diversity of accrual to a multicenter clinical trial. METHODS Alliance 191901 (GETSET) is a national randomized controlled trial testing interventions to promote breast cancer endocrine therapy adherence, which oversamples Black women and those under age 50 years at 30% thresholds. A secondary study objective is to examine site-level factors associated with accrual of Black and younger participants. At 50% accrual to the parent study, we performed prespecified analyses of association between site characteristics (region, neighborhood racial composition, Alliance membership type, number of recent accruals to cooperative research group trials) and the proportion of Black patients and younger patients accrued. We also examined trajectories of accrual over time for race- and age-specified subgroups. RESULTS The analysis included 124 sites. Among 590 participants, 9.7% were Black, and 22.4% were age <50 years. Neither site type nor historical accrual volume was associated with Black participant recruitment. Southern sites recruited higher proportions of Black participants (19.0% v 7.3% for West, P < .001). Neighborhood racial composition was positively associated with recruitment of Black participants (16.2% at sites from highest Black composition v 1.4% in lowest, P < .01). Recruitment trajectories of Black participants were slower than target rates, whereas those among non-Black participants were faster. CONCLUSION Neighborhood composition and geographic region were predictors of proportions of Black participants accrued to A191901 sites, but site type and historical accrual volume were not. When trials must limit site selection, identifying sites based on neighborhood composition and geography may be an appropriate tool for increasing trial diversity.
AAPM task group 317 report: A joint AAPM and ESTRO report on brachytherapy catheter, needle, and applicator tracking technology
Battisti, Maxence Borot de, Cunha, J. Adam M. , Damato, Antonio L. , Deufel, Christopher L. , Hautvast, Gilion, Hsu, I‐Chow , Kolkman‐Deurloo, Inger‐Karine K. , Moerland, Marinus A. , Niatsetski, Yury , Beaulieu, Luc , Bert, Christoph , Cormack, Robert A. , Weersink, Robert , Tanderup, Kari

Mayo Clinic

Medical Physics | October 7, 2025 | Volume: 52 | Issue: 10 | Pages: No page available

10.1002/mp.70037 | PMID 41805152 Get It

Abstract In recent years, various tracking technologies that work independently of imaging systems have been proposed to automate, simplify, and enhance various tasks in the brachytherapy treatment workflow. These tasks, critical to the overall accuracy of the therapeutic dose delivery, include applicator, catheter and needle insertion guidance, and reconstruction as well as transfer tube connection in afterloading technique. Task Group 317 was established as a joint American Association of Physicists in Medicine (AAPM) and European Society for Radiotherapy and Oncology (ESTRO) committee to review: the current state‐of‐the‐art scientific literature as it pertains to tracking technology in the field of brachytherapy; the benefits and issues related to the use of the technology for automated reconstruction of brachytherapy implants, quality control (QC) tasks such as channel path and tip reconstruction, and real‐time guidance tasks; their limitations, in particular in the clinical environment and, finally, to develop recommendations related to commissioning, quality assurance (QA) and clinical use. The Task Group has looked in detail at key tracking technologies in advanced brachytherapy applications: infrared, electromagnetic, fiber optic shape sensing (fiber Bragg grating), and active radiofrequency coil tracking. For each, the performance and accuracy in well‐controlled conditions as well as in clinically relevant environments are provided. Guidelines for clinical implementations, including target accuracy and performance needed for critical tasks, are summarized. Risk‐based analysis is discussed in the context of an electromagnetic‐based tracking system used as part of a clinical trial. The report concludes with the essential elements of an effective quality management program dedicated to the advanced features enabled by the above‐described technology.